7-Hydroxymitragynine (7-OH)

psilodex.org/m/7-hydroxymitragynine · data v2026.10.02

Clinical contraindication: Relative; Substantial clinical concern; the literature treats it as a reason for caution or deferral.
Best available evidence: Case reports; Also: mechanism only.
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: 7-hydroxymitragynine · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

CR · Th

Concentrated kratom alkaloid sold as tablets, gummies and shots; an opioid that can be more potent than morphine. FDA cites respiratory depression, seizures, addiction and withdrawal. Plain kratom leaf contains only trace 7-OH and has a separate record.

Human data with psilocybin: Case reports or surveys only

Evidence types on this record

CRCase reports or online surveys

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [2][4]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Any change to the dose is the prescriber’s decision. Sources [1][2][4]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

US FDA consumer or public-health page (per-entry link) — addiction, seizures and withdrawal reported; sold as tablets, gummies, drink mixes, shots
US Food and Drug Administration. Concentrated 7-OH opioid products (FDA report to HHS supporting scheduling recommendation), July 2025. — 13x morphine potency in one study; fatal respiratory depression; addiction and withdrawal; trace amounts in kratom leaf
US FDA consumer or public-health page (per-entry link) — July 29, 2025 FDA recommendation to schedule 7-OH
Drug Enforcement Administration. Schedules of controlled substances: temporary placement of 7-hydroxymitragynine above a specified threshold in Schedule I (notice of intent). Federal Register, July 6, 2026 (FR Doc. 2026-13580). — notice of intent, temporary Schedule I; opioid profile similar to morphine; tolerance, dependence, respiratory depression

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →